國立虎尾科技大學 |

Algae-based biopharmaceuticals

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Algae-based biopharmaceuticals/ by Sergio Rosales-Mendoza.
Author:	Rosales-Mendoza, Sergio.
Published:	Cham :Springer International Publishing : : 2016.,
Description:	x, 166 p. :ill., digital ; : 24 cm.;
Contained By:	Springer eBooks
Subject:	Biopharmaceutics. -
Online resource:	http://dx.doi.org/10.1007/978-3-319-32232-2
ISBN:	9783319322322

Algae-based biopharmaceuticals
Rosales-Mendoza, Sergio.

Algae-based biopharmaceuticals[electronic resource] /by Sergio Rosales-Mendoza. - Cham :Springer International Publishing :2016. - x, 166 p. :ill., digital ;24 cm.

The Biopharmaceuticals Field and Algae as Expression Hosts -- Genetic Engineering Approaches for Algae -- Algae-made Vaccines Targeting Human Diseases -- Algae-made Vaccines Targeting Animal Pathogens -- Algae-made Antibodies and Immunotoxins -- Algae-made Cytokines and Growth Factors -- Other Biopharmaceuticals Produced in Algae -- Algae-made Nutraceuticals -- Perspectives for the Algae-made Biopharmaceuticals Field.

This book constitutes a key reference on the use of algae in the BFs production field; providing an updated outlook on the achievements accomplished thus far and transmitting a prospective view for this biotechnological application. This book provides a detailed description of the technology as well as an updated outlook of the strides achieved thus far in the field of algae-based biopharmaceuticals. Algae constitute attractive expression hosts for the production of recombinant proteins with medical applications. Among the features that make them attractive candidates are: low cost, fast growth, wide biosynthetic capacity, and absence of human pathogens; which constitute substantial advantages with respect to bacterial and mammalian systems. First, the features of algae as convenient hosts for the production of BFs are analyzed in terms of production costs, biosynthetic capacity, and safety (Chapter 1) Second, the genetic engineering tools for algae-species are described. Nuclear and chloroplast-based expression approaches are analyzed and compared in terms of biosynthetic advantages, gene expression complexity, and DNA transfer approaches (Chapter 2) In the following sections, chapters 3 to 7, the state of the art on producing distinct types of BFs in algae species is presented. Although this book is mainly focused on BFs, considering that the production of compounds with health-promoting properties are achieved using genetically-engineered algae strains, chapter 8 deals with nutraceuticals. In the ninth chapter, the developments reported thus far are placed in perspective and challenges for the field are discussed. Critical future prospects comprise the following: optimizing large-scale production in bioreactors, implementing glycoengineering approaches, optimizing nuclear expression, exploring new approaches for oral delivery, and implementing regulatory frameworks to accomplish technology transfer and regulatory approval of algae-made BFs.

ISBN: 9783319322322

Standard No.: 10.1007/978-3-319-32232-2doiSubjects--Topical Terms:

582678
Biopharmaceutics.

LC Class. No.: RM301.4

Dewey Class. No.: 615.3298

Algae-based biopharmaceuticals
LDR:03383nam a2200337 a 4500 001 864035
003 DE-He213
005 20161019140328.0
006 m d
007 cr nn 008maaau
008 170720s2016 gw s 0 eng d
020 $a 9783319322322 $q (electronic bk.)
020 $a 9783319322308 $q (paper)
024 7 $a 10.1007/978-3-319-32232-2 $2 doi
035 $a 978-3-319-32232-2
040 $a GP $c GP
041 0 $a eng
050 4 $a RM301.4
072 7 $a PSTL $2 bicssc
072 7 $a TCB $2 bicssc
072 7 $a SCI011000 $2 bisacsh
072 7 $a SCI010000 $2 bisacsh
082 0 4 $a 615.3298 $2 23
090 $a RM301.4 $b .R788 2016
100 1 $a Rosales-Mendoza, Sergio. $3 1108613
245 1 0 $a Algae-based biopharmaceuticals $h [electronic resource] / $c by Sergio Rosales-Mendoza.
260 $a Cham : $c 2016. $b Springer International Publishing : $b Imprint: Springer,
300 $a x, 166 p. : $b ill., digital ; $c 24 cm.
505 0 $a The Biopharmaceuticals Field and Algae as Expression Hosts -- Genetic Engineering Approaches for Algae -- Algae-made Vaccines Targeting Human Diseases -- Algae-made Vaccines Targeting Animal Pathogens -- Algae-made Antibodies and Immunotoxins -- Algae-made Cytokines and Growth Factors -- Other Biopharmaceuticals Produced in Algae -- Algae-made Nutraceuticals -- Perspectives for the Algae-made Biopharmaceuticals Field.
520 $a This book constitutes a key reference on the use of algae in the BFs production field; providing an updated outlook on the achievements accomplished thus far and transmitting a prospective view for this biotechnological application. This book provides a detailed description of the technology as well as an updated outlook of the strides achieved thus far in the field of algae-based biopharmaceuticals. Algae constitute attractive expression hosts for the production of recombinant proteins with medical applications. Among the features that make them attractive candidates are: low cost, fast growth, wide biosynthetic capacity, and absence of human pathogens; which constitute substantial advantages with respect to bacterial and mammalian systems. First, the features of algae as convenient hosts for the production of BFs are analyzed in terms of production costs, biosynthetic capacity, and safety (Chapter 1) Second, the genetic engineering tools for algae-species are described. Nuclear and chloroplast-based expression approaches are analyzed and compared in terms of biosynthetic advantages, gene expression complexity, and DNA transfer approaches (Chapter 2) In the following sections, chapters 3 to 7, the state of the art on producing distinct types of BFs in algae species is presented. Although this book is mainly focused on BFs, considering that the production of compounds with health-promoting properties are achieved using genetically-engineered algae strains, chapter 8 deals with nutraceuticals. In the ninth chapter, the developments reported thus far are placed in perspective and challenges for the field are discussed. Critical future prospects comprise the following: optimizing large-scale production in bioreactors, implementing glycoengineering approaches, optimizing nuclear expression, exploring new approaches for oral delivery, and implementing regulatory frameworks to accomplish technology transfer and regulatory approval of algae-made BFs.
650 0 $a Biopharmaceutics. $3 582678
650 0 $a Algae $x Biotechnology. $3 882396
650 0 $a Pharmaceutical biotechnology. $3 582896
650 1 4 $a Life Sciences. $3 593888
650 2 4 $a Plant Breeding/Biotechnology. $3 677715
650 2 4 $a Freshwater & Marine Ecology. $3 676940
650 2 4 $a Pharmaceutical Sciences/Technology. $3 768561
650 2 4 $a Plant Anatomy/Development. $3 668688
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-32232-2
950 $a Biomedical and Life Sciences (Springer-11642)